Clinical Flow Cytometry Panels Patents: Who Leads, Where the Gaps Are 2026
Clinical Flow Cytometry Panels: Mapping the Patents Behind MRD and Immunophenotyping Workflows
48.6% concentration. The top five assignees hold 779 of 1,604 records in scope — a field with a genuine head, not a flat field of small filers. Filings reached a peak of 179 in 2017. The 2021→2024 window — the most recent span not distorted by publication lag — moved from 102 to 71 records, a -30% change. Counts for 2025 and 2026 are still filling in and should not be read as a further decline.
- 1THE TRUSTEES OF THE UNIV OF PENNSYLVANIA355
- 2NOVARTIS AG227
- 3THE CHILDRENS HOSPITAL OF PHILADELPHIA84
- 4CELGENE CORP61
- 5REGENERON PHARMACEUTICALS INC52
See the full clinical flow cytometry panels analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions on this landscape
Who holds the most patents in clinical flow cytometry panels?
Filing is concentrated: the leading assignee alone holds 355 of the 1,604 records in scope, and the top five combined hold 779 records (48.6%). Most of this concentration traces to academic-medical centres and pharmaceutical companies working on CAR-T and related cell-therapy programmes, where flow cytometry panels are used for immunophenotyping and minimal residual disease monitoring. Below the top ten, filing activity spreads across a long tail of assignees with far fewer records each, so a full freedom-to-operate check needs to look well past the leaders.
Is patent filing in this field growing or slowing?
Filings peaked in 2017 at 179 records and have since settled lower. The most reliable recent comparison, 2021 to 2024, shows a -30% change (102 down to 71 records), and 2024 is the most recent year that can be treated as reasonably complete. Figures for 2025 and 2026 are still incomplete because publication typically lags filing by around 18 months, so they should not yet be read as confirming a continued decline.
What does WO2026017800A1 actually cover?
WO2026017800A1, filed by Medical University – Plovdiv and published in January 2026, claims a reagent panel for detecting minimal residual disease in pediatric B-cell precursor acute lymphoblastic leukemia using multiparametric flow cytometry. The claimed panel specifies a defined combination of fluorochrome-conjugated antibodies against a named set of markers including CD45, CD34, CD38, CD10 and CD371, alongside CD19 and/or CD22. Anyone building a similar pediatric B-ALL MRD panel with an overlapping marker combination and conjugation scheme should review this filing’s exact claim scope before finalising a panel design.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Clinical Flow Cytometry Panels covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.